Author

J. Day

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Patterns of care, outcomes, and prognostics for transformed follicular lymphoma in the rituximab era.

Histologic transformation (HT) is the leading of death in follicular lymphoma (FL), yet outcomes remain poorly defined due to small cohorts and heterogenous definitions. To characterize outcomes and treatment patterns in the rituximab era we analyzed 344 patients with an initial biopsy-confirmed FL diagnosis between 20...

J. Day, M. Larson, C. Casulo et al. · Haematologica · 0 citations

Review Open access Jul 2026

Safety, feasibility, and efficacy of anti-PD-1 therapy for the treatment of classical Hodgkin lymphoma.

The clinical paradigm for treatment of classical Hodgkin lymphoma has been transformed by the use of anti-PD-1 therapy, driven by foundational work revealing near-universal 9p24.1 alterations resulting in overexpression of PD-L1 and PD-L2 on Reed-Sternberg cells. Use of PD-1 inhibitors has demonstrated remarkable clini...

J. Day, Stephen M. Ansell · Haematologica · 0 citations

Review

Safety, feasibility

This review seeks to examine the safety, efficacy, and feasibility of anti-PD-1 therapy in classical Hodgkin lymphoma.

J. Day, S. Ansell, Takeda Regeneron AstraZeneca Pfizer Affimed StepPharma Bristol Myers Squibb et al. · 0 citations